Baseline and follow-up assessment
death
DISEASE PROGRESSION, ADVERSE EVENT
The pretreatment evaluation included detailed medical history, physical examination, routine laboratory tests, and computed tomography (CT) of measurable lesions at baseline. Laboratory tests included blood routine, liver function, renal function, electrolytes, and urinalysis. CT was conducted for efficacy evaluation every two cycles for the first 4–6 cycles, and then every 2–3 months until disease progression. Adverse events (AEs) were recorded at each cycle until 30 days after the last dose therapy. Subjects were observed until death, loss to follow-up, withdrawal from the trial, or the end of this study.